viruses that constitute a major threat to human health. The IAV genome 13 consists of eight RNA segments contained in separate viral ribonucleoprotein 14 complexes (vRNPs) that are packaged together into a single virus particle 1,2 . 15
. However, due to a lack of understanding of the molecular 37 mechanisms governing the packaging of the eight genome segments into a single 38 virion, it remains unclear which influenza virus strains have the potential to form 39 reassortants. In virions, as well as in infected cells, the RNA genome segments are 40 assembled into viral ribonucleoprotein (vRNP) complexes in which the termini of 41 the viral RNA (vRNA) associate with the viral RNA-dependent RNA polymerase 42 while the rest of the vRNA is bound by oligomeric nucleoprotein (NP) 2, 7 . Although 43 3 cryo-EM studies revealed the overall architecture and organisation of vRNPs, the 44 resolution of currently available structures is not sufficiently high to provide 45 information about the conformation of the vRNA 8, 9 . It is thought that, through 46 specific RNA-RNA interactions, exposed regions of vRNA in the vRNP mediate 47 segment-specific interactions during virion assembly, ensuring that the correct set 48 of eight vRNPs is selected 3, 4 . However, the identities of these interacting regions as 49 well as the overall structure of vRNA in vRNPs are currently unknown. 50
51
To better understand the vRNA structure in the context of vRNPs, we employed 52
SHAPE-MaP (Selective 2'-Hydroxyl Acylation Analysed by Primer Extension and 53
Mutational Profiling), which probes the conformational flexibility of each vRNA 54 nucleotide both ex virio and in virio (Extended Data Fig. 1 ) 10, 11 . For the ex virio 55 experiments, the eight vRNA segments were individually transcribed from plasmid 56 DNA using T7 RNA polymerase (ivtRNA) or "naked" vRNA was purified from 57 ultracentrifugation: firstly, the infected cell culture medium was clarified by 227 centrifugation at 4000 rpm for 10 min at 4°C followed by centrifugation at 10,000 228 rpm for 15 min at 4°C. The virus was then purified by centrifugation through a 30% 229 sucrose cushion at 25,000 rpm for 90 min at 4°C in a SW32 rotor (Beckman Coulter). 230
The purified virus pellet was resuspended in a resuspension buffer (0.01 M Tris-HCl 231 (pH 7.4), 0.1 M NaCl, 0.0001 M EDTA). Viruses containing synonymous mutations 232 were produced using the 12-plasmid rescue system as described previously 29 . 1-methyl-7-nitroisatoic anhydride (1M7) was custom synthesised from 4-248 nitroisatoic anhydride as described previously 30 . For the ivtRNA experiments each 249 vRNA segment was synthesised from a linear DNA template using the HiScribe™ T7 250 10 High Yield RNA Synthesis Kit (NEB). The products were checked for size and purity 251 on a 3.5% PAGE-urea gel. nkvRNA samples were prepared by purifying the WSN 252 particles over sucrose cushion as described above. Purified viruses were treated 253 with 250 μg/mL of Proteinase K (Roche) in PK buffer (10 mM Tris-HCl (pH 7.0), 100 254 mM NaCl, 1 mM EDTA, 0.5% SDS) for 40 min at 37°C. Before the modification 255 ivtRNA and nkvRNA samples were folded at 37°C for 30 min in folding buffer (100 256 mM Hepes-NaOH (pH 8.0), 100 mM NaCl, 10 mM MgCl2). 1M7 (dissolved in 257 anhydrous DMSO (Merck)) was added to a final concentration of 10 mM to the 258 folded RNA and the samples were incubated for 75 s at 37°C. The in virio 259 modifications were performed by adding 1M7 directly to the purified virus stocks. 260
The ability of SHAPE reagents to penetrate viral particles was initially tested as 261 described previously 31 by preforming 32 P-labelled primer extensions on RNA 262 extracted from SHAPE reagent-treated viral stocks using an NA segment targeting 263 primer (5'-AATTGGTTCCAAAGGAGACG-3'). In parallel to the 1M7-treated samples, 264 control samples were treated with DMSO. RNA extracted from purified viral 265 particles or denatured T7 RNA polymerase transcribed RNA was used for denatured 266 controls (DC). To prepare DC samples the RNA was mixed in DC buffer (50 mM 267
Hepes-NaOH (pH 8.0), 4 mM EDTA) with 55 % formamide and incubated at 95°C for 268 1 min. 1M7 was then added to 10 µM and the samples were incubated at 95°C for 269 an additional 1 min. N-methylisatoic anhydride (NMIA, Thermo Fisher) SHAPE 270 reagent was also tested in virio. Experiments with NMIA were preformed as 271 described above for 1M7, except the purified virions were treated with NMIA for 45 272 min. 273 274 Sequencing library preparation was done as described previously 11 following the 275 randomer workflow. In brief, after 1M7 or control treatments, RNA was cleaned up 276 using the RNA Clean & Concentrator™-5 kit (Zymo Research). The RNA was reverse 277 transcribed using Random Primer Mix (NEB) with Superscript II in MaP buffer (50 278 mM Tris-HCl (pH 8.0), 75 mM KCl, 6 mM MnCl2, 10 mM DTT and 0.5 mM dNTPs). 279 Nextera XT DNA Library Prep Kit (Illumina) was used to prepare the DNA libraries. 280
Final PCR amplification products were size selected using Agencourt AMPure XP 281 beads (Beckman Coulter) and quality assessed using the Agilent DNA 1000 kit on a 282 Streptavidin C1 beads (Life Technologies) and on-bead proximity ligation and 300 psoralen crosslink reversal were carried out as published previously. Sequencing 301 libraries were prepared using adaptor ligation as described 22, 32 for the first SPLASH 302 experiment, and using the commercial SMARTer smRNA-Seq Kit (Clontech) for the 303 second SPLASH experiment. Final size selection was done by running the PCR-304 amplified sequencing libraries on a 6% PAGE gel (Thermo Thermo Fisher Fisher) in 305 TBE and selecting for 200-300bp DNA. Libraries were sequenced either 1x or 306 2x150bp on a NextSeq 500 instrument (Illumina). 307
308

Processing of SHAPE-MaP sequencing reads 309
The sequencing reads were trimmed to remove adaptors using Skewer
33
. The 310 SHAPE reactivity profiles were generated using the published ShapeMapper 311 pipeline 11 , which aligns the reads to the reference genome using Bowtie 2 and 312 calculates mutation rates at each nucleotide position. The mutation rates are then 313 converted to the SHAPE reactivity values defined as: 314
, where mutr1M7 is the nucleotide mutation rate in 1M7 treated sample, mutr1M7 is 315 the mutation rate in the DMSO treated sample and mutrDC is the mutation rate in 316 the denatured control. All SHAPE reactivities are normalised to an approximate 0-2 317 scale by dividing the SHAPE reactivity values by the average reactivity of the 10% 318 most highly reactive nucleotides after excluding outliers (defined as nucleotides 319
with reactivity values that are greater than 1.5x the interquartile range). 320 321
Processing of SPLASH sequencing reads 322
The sequencing reads were first deduplicated using clumpify.sh (BBMap package; 323 https://sourceforge.net/projects/bbmap/) and adaptors were trimmed using 324 Align to virus reference genome and count mutation rates Convert mutation rates to SHAPE reactivity values Use SHAPE-rectivity as pseudoenergy constraint in structure predictions
1M7 modification
Mutation site Low SHAPE = more structure High SHAPE = less structure Number of Interactions (log₂) 
